Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Aug;261(7):393-6.
doi: 10.1007/s00405-003-0688-6. Epub 2003 Oct 29.

Should Hyperbaric Oxygen Be Added to Treatment in Idiopathic Sudden Sensorineural Hearing Loss?

Clinical Trial

Should Hyperbaric Oxygen Be Added to Treatment in Idiopathic Sudden Sensorineural Hearing Loss?

Ebru Topuz et al. Eur Arch Otorhinolaryngol. .


At present, there is still no agreement about the therapy of idiopathic sudden sensorineural hearing loss (ISSHL). Hyperbaric oxygen (HBO) is used in the therapy of ISSHL to increase the partial oxygen pressure and the oxygen concentration in the inner ear and also to improve the blood profile and the microcirculation. In our prospective randomized study, we aimed to investigate the therapeutic effects of HBO therapy in the 1st 2 weeks of the onset of ISSHL. Fifty-one hospitalized patients with confirmed ISSHL who had received therapy were grouped randomly into two groups. Twenty-one patients (group I) received steroids, plasma expander dextrans (rheomacrodex), diazepam, pentoxiphylline and salt restriction, and 30 patients (group II) received the same basic treatment with the addition of HBO therapy. Audiological assessments of the patients were performed before and after the treatment. The hearing gains at frequencies of 250, 500, 1,000, 2,000 and 4,000 Hz were calculated separately. The level of hearing loss at the five frequencies was assessed in three groups at the first visit: equal or below 60 dB, between 61-80 dB and equal or above 81 dB. The average of the mean hearing gains at the five frequencies of the patients according to the age groups in group II was compared. The mean hearing gains at the five frequencies were compared between the two groups, and statistically significant improvement was detected in all the frequencies except at 2,000 Hz in group II. The mean hearing gains in group II were found to be significantly high in patients with initial hearing levels up to 60 dB in comparison to patients with initial hearing levels below 60 dB. When age groups and mean hearing gains were compared, there was no statistically significant difference in group I. In group II, the mean hearing gains were 39.1+/-18.3 dB in patients younger than 50 years and 22.7+/-11.3 dB in patients older than 50 years ( P=0.044). In conclusion, the addition of HBO therapy to conventional treatment modalities significantly improves the outcome of ISSHL, especially at the frequencies of 250, 500, 1,000 and 4,000 Hz and in hearing loss of above 61 dB. Furthermore, HBO therapy was found to be more effective in patients younger than 50 years.

Comment in

  • HBO effectively supports SSNHL therapy.
    Narozny W, Kuczkowski J, Mikaszewski B. Narozny W, et al. Eur Arch Otorhinolaryngol. 2005 Feb;262(2):163-4. doi: 10.1007/s00405-004-0741-0. Epub 2004 Mar 4. Eur Arch Otorhinolaryngol. 2005. PMID: 14999508 No abstract available.

Similar articles

See all similar articles

Cited by 20 articles

See all "Cited by" articles


    1. Adv Otorhinolaryngol. 1998;54:1-13 - PubMed
    1. Rev Laryngol Otol Rhinol (Bord). 1970 Nov-Dec;91(11):951-72 - PubMed
    1. HNO. 1971 Dec;19(12):363-9 - PubMed
    1. HNO. 1988 Sep;36(9):363-6 - PubMed
    1. Acta Otolaryngol. 1983 Jul-Aug;96(1-2):57-68 - PubMed

Publication types

LinkOut - more resources